亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

左乙拉西坦 斯特罗普效应 临床痴呆评级 认知 癫痫 随机对照试验 医学 交叉研究 安慰剂 痴呆 心理学 听力学 物理疗法 精神科 疾病 内科学 认知障碍 替代医学 病理
作者
Keith A. Vossel,Kamalini G. Ranasinghe,Alexander J. Beagle,Alice L. La,Kasey Ah Pook,Madelyn R. Castro,Danielle Mizuiri,Susanne M. Honma,Nisha Venkateswaran,MARY E. KOESTLER,Wenbo Zhang,Lennart Mucke,Michael J. Howell,Katherine L. Possin,Joel H. Kramer,Adam L. Boxer,Bruce L. Miller,Srikantan S. Nagarajan,Heidi E. Kirsch
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:78 (11): 1345-1345 被引量:272
标识
DOI:10.1001/jamaneurol.2021.3310
摘要

Importance: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). Objective: To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD. Design, Setting, and Participants: The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was a phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD that was conducted at the University of California, San Francisco, and the University of Minnesota, Twin Cities, between October 16, 2014, and July 21, 2020. Participants were adults 80 years and younger who had a Mini-Mental State Examination score of 18 points or higher and/or a Clinical Dementia Rating score of less than 2 points. Screening included overnight video electroencephalography and a 1-hour resting magnetoencephalography examination. Interventions: Group A received placebo twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, twice daily for 4 weeks. Group B received treatment using the reverse sequence. Main Outcomes and Measures: The primary outcome was the ability of levetiracetam treatment to improve executive function (measured by the National Institutes of Health Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research [NIH-EXAMINER] composite score). Secondary outcomes were cognition (measured by the Stroop Color and Word Test [Stroop] interference naming subscale and the Alzheimer's Disease Assessment Scale-Cognitive Subscale) and disability. Exploratory outcomes included performance on a virtual route learning test and scores on cognitive and functional tests among participants with epileptiform activity. Results: Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate. A total of 34 adults (21 women [61.8%]; mean [SD] age, 62.3 [7.7] years) with AD were enrolled and randomized (17 participants to group A and 17 participants to group B). Thirteen participants (38.2%) were categorized as having epileptiform activity. In total, 28 participants (82.4%) completed the study, 10 of whom (35.7%) had epileptiform activity. Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scores (mean difference vs placebo, 0.07 points; 95% CI, -0.18 to 0.32 points; P = .55) or secondary measures. However, among participants with epileptiform activity, levetiracetam treatment improved performance on the Stroop interference naming subscale (net improvement vs placebo, 7.4 points; 95% CI, 0.2-14.7 points; P = .046) and the virtual route learning test (t = 2.36; Cohen f2 = 0.11; P = .02). There were no treatment discontinuations because of adverse events. Conclusions and Relevance: In this randomized clinical trial, levetiracetam was well tolerated and, although it did not improve the primary outcome, in prespecified analysis, levetiracetam improved performance on spatial memory and executive function tasks in patients with AD and epileptiform activity. These exploratory findings warrant further assessment of antiseizure approaches in AD. Trial Registration: ClinicalTrials.gov Identifier: NCT02002819.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ddl30完成签到,获得积分10
4秒前
阔达的沛岚完成签到,获得积分10
14秒前
丸总完成签到,获得积分10
25秒前
江渕完成签到,获得积分10
26秒前
27秒前
CodeCraft的应助被丸总采纳,获得10
29秒前
31秒前
u583484发布了新的文献求助30
37秒前
健忘香彤完成签到,获得积分10
38秒前
u501249发布了新的文献求助30
44秒前
畅快的夜云完成签到,获得积分10
44秒前
45秒前
u766482发布了新的文献求助30
49秒前
1分钟前
u501249发布了新的文献求助30
1分钟前
小蘑菇的应助被2589采纳,获得10
1分钟前
wxy小白鼠发布了新的文献求助10
1分钟前
无奈小玉完成签到,获得积分10
1分钟前
1分钟前
甜美凝琴完成签到,获得积分10
1分钟前
u766482发布了新的文献求助30
1分钟前
Maestro_S的应助被LJH采纳,获得10
1分钟前
阿苏完成签到,获得积分10
1分钟前
2分钟前
u516929发布了新的文献求助30
2分钟前
2分钟前
2589发布了新的文献求助10
2分钟前
2分钟前
紧张的向雁完成签到,获得积分10
2分钟前
lin发布了新的文献求助10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185169
求助须知:如何正确求助?哪些是违规求助? 9574060
关于积分的说明 21834167
捐赠科研通 7782677
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558771
邀请新用户注册赠送积分活动 2481208